-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 14, Chia Tai Tianqing Pharmaceutical Group submitted a Category 4 generic listing application for Pipercelli Capsules
.
Pilbociclib is an anti-tumor drug with global sales of over US$5 billion for Pfizer.
Qilu won the first domestic imitation in December 2020.
With the strong entry of Chia Tai Tianqing, the number of domestically-made second companies has reached 8
.
.
Pilbociclib is an anti-tumor drug with global sales of over US$5 billion for Pfizer.
Qilu won the first domestic imitation in December 2020.
With the strong entry of Chia Tai Tianqing, the number of domestically-made second companies has reached 8
.
Figure 1: The latest products declared by Chia Tai Tianqing Pharmaceutical Group
Source: CDE official website
It is reported that palbociclib was first developed by Pfizer and is the first CDK4/6 inhibitor to be marketed in the world.
In 2021, the global sales of the original product will exceed 5.
4 billion US dollars
.
In 2021, the global sales of the original product will exceed 5.
4 billion US dollars
.
Figure 2: Sales of Palbociclib Capsules in the Retail Market (Unit: 10,000 yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
Pfizer's piperacillin capsule was approved to enter the domestic market in July 2018, and has not yet entered medical insurance.
Therefore, the product is widely used in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The sales of terminals have not yet achieved a large volume, with only 60 million yuan in 2020, and a growth rate of 52.
70% in the first half of 2021
.
According to the data from Minet.
com, piperacillin capsules are showing an explosive growth trend in physical pharmacy terminals in Chinese cities, and the sales in 2021 are expected to be close to 100 million yuan
.
Therefore, the product is widely used in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The sales of terminals have not yet achieved a large volume, with only 60 million yuan in 2020, and a growth rate of 52.
70% in the first half of 2021
.
According to the data from Minet.
com, piperacillin capsules are showing an explosive growth trend in physical pharmacy terminals in Chinese cities, and the sales in 2021 are expected to be close to 100 million yuan
.
Table 1: Application for generic listing of Palbociclib Capsules
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
The excellent performance of piperacillin capsules in the global and domestic markets has attracted the attention of many domestic pharmaceutical companies.
So far, 10 domestic companies have applied for 4 types of generic listings
.
So far, 10 domestic companies have applied for 4 types of generic listings
.
Qilu won the first domestic imitation in 2020.
At present, 7 companies including Jiangsu Hansoh Pharmaceutical Group are under review and approval.
CP Tianqing Pharmaceutical Group has officially entered the market this time, and the competition for the second domestically produced product will be more intense.
.
At present, 7 companies including Jiangsu Hansoh Pharmaceutical Group are under review and approval.
CP Tianqing Pharmaceutical Group has officially entered the market this time, and the competition for the second domestically produced product will be more intense.
.
Source: CDE official website, Minet database
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 15, if there are any omissions, please correct me!
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 15, if there are any omissions, please correct me!
On April 14, Chia Tai Tianqing Pharmaceutical Group submitted a Category 4 generic listing application for Pipercelli Capsules
.
Pilbociclib is an anti-tumor drug with global sales of over US$5 billion for Pfizer.
Qilu won the first domestic imitation in December 2020.
With the strong entry of Chia Tai Tianqing, the number of domestically-made second companies has reached 8
.
.
Pilbociclib is an anti-tumor drug with global sales of over US$5 billion for Pfizer.
Qilu won the first domestic imitation in December 2020.
With the strong entry of Chia Tai Tianqing, the number of domestically-made second companies has reached 8
.
Figure 1: The latest products declared by Chia Tai Tianqing Pharmaceutical Group
Source: CDE official website
It is reported that palbociclib was first developed by Pfizer and is the first CDK4/6 inhibitor to be marketed in the world.
In 2021, the global sales of the original product will exceed 5.
4 billion US dollars
.
In 2021, the global sales of the original product will exceed 5.
4 billion US dollars
.
Figure 2: Sales of Palbociclib Capsules in the Retail Market (Unit: 10,000 yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
Pfizer's piperacillin capsule was approved to enter the domestic market in July 2018, and has not yet entered medical insurance.
Therefore, the product is widely used in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The sales of terminals have not yet achieved a large volume, with only 60 million yuan in 2020, and a growth rate of 52.
70% in the first half of 2021
.
According to the data from Minet.
com, piperacillin capsules are showing an explosive growth trend in physical pharmacy terminals in Chinese cities, and the sales in 2021 are expected to be close to 100 million yuan
.
Therefore, the product is widely used in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The sales of terminals have not yet achieved a large volume, with only 60 million yuan in 2020, and a growth rate of 52.
70% in the first half of 2021
.
According to the data from Minet.
com, piperacillin capsules are showing an explosive growth trend in physical pharmacy terminals in Chinese cities, and the sales in 2021 are expected to be close to 100 million yuan
.
Table 1: Application for generic listing of Palbociclib Capsules
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
The excellent performance of piperacillin capsules in the global and domestic markets has attracted the attention of many domestic pharmaceutical companies.
So far, 10 domestic companies have applied for 4 types of generic listings
.
So far, 10 domestic companies have applied for 4 types of generic listings
.
Qilu won the first domestic imitation in 2020.
At present, 7 companies including Jiangsu Hansoh Pharmaceutical Group are under review and approval.
CP Tianqing Pharmaceutical Group has officially entered the market this time, and the competition for the second domestically produced product will be more intense.
.
At present, 7 companies including Jiangsu Hansoh Pharmaceutical Group are under review and approval.
CP Tianqing Pharmaceutical Group has officially entered the market this time, and the competition for the second domestically produced product will be more intense.
.
Source: CDE official website, Minet database
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 15, if there are any omissions, please correct me!
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 15, if there are any omissions, please correct me!
On April 14, Chia Tai Tianqing Pharmaceutical Group submitted a Category 4 generic listing application for Pipercelli Capsules
.
Pilbociclib is an anti-tumor drug with global sales of over US$5 billion for Pfizer.
Qilu won the first domestic imitation in December 2020.
With the strong entry of Chia Tai Tianqing, the number of domestically-made second companies has reached 8
.
.
Pilbociclib is an anti-tumor drug with global sales of over US$5 billion for Pfizer.
Qilu won the first domestic imitation in December 2020.
With the strong entry of Chia Tai Tianqing, the number of domestically-made second companies has reached 8
.
Figure 1: The latest products declared by Chia Tai Tianqing Pharmaceutical Group
Source: CDE official website
It is reported that palbociclib was first developed by Pfizer and is the first CDK4/6 inhibitor to be marketed in the world.
In 2021, the global sales of the original product will exceed 5.
4 billion US dollars
.
In 2021, the global sales of the original product will exceed 5.
4 billion US dollars
.
Figure 2: Sales of Palbociclib Capsules in the Retail Market (Unit: 10,000 yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
Pfizer's piperacillin capsule was approved to enter the domestic market in July 2018, and has not yet entered medical insurance.
Therefore, the product is widely used in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The sales of terminals have not yet achieved a large volume, with only 60 million yuan in 2020, and a growth rate of 52.
70% in the first half of 2021
.
According to the data from Minet.
com, piperacillin capsules are showing an explosive growth trend in physical pharmacy terminals in Chinese cities, and the sales in 2021 are expected to be close to 100 million yuan
.
Hospital Hospital Hospital Pharmacy Pharmacy PharmacyTherefore, the product is widely used in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The sales of terminals have not yet achieved a large volume, with only 60 million yuan in 2020, and a growth rate of 52.
70% in the first half of 2021
.
According to the data from Minet.
com, piperacillin capsules are showing an explosive growth trend in physical pharmacy terminals in Chinese cities, and the sales in 2021 are expected to be close to 100 million yuan
.
Table 1: Application for generic listing of Palbociclib Capsules
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
The excellent performance of piperacillin capsules in the global and domestic markets has attracted the attention of many domestic pharmaceutical companies.
So far, 10 domestic companies have applied for 4 types of generic listings
.
enterprise enterprise enterpriseSo far, 10 domestic companies have applied for 4 types of generic listings
.
Qilu won the first domestic imitation in 2020.
At present, 7 companies including Jiangsu Hansoh Pharmaceutical Group are under review and approval.
CP Tianqing Pharmaceutical Group has officially entered the market this time, and the competition for the second domestically produced product will be more intense.
.
At present, 7 companies including Jiangsu Hansoh Pharmaceutical Group are under review and approval.
CP Tianqing Pharmaceutical Group has officially entered the market this time, and the competition for the second domestically produced product will be more intense.
.
Source: CDE official website, Minet database
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 15, if there are any omissions, please correct me!
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of April 15, if there are any omissions, please correct me!
